Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Dec;197(12):1151-1153.
doi: 10.1007/s00066-021-01864-4. Epub 2021 Oct 26.

[Relevance of radiotherapy in the context of increasingly effective systemic therapies for metastatic NSCLC-evidence from a recurrence analysis after immune checkpoint inhibitors]

[Article in German]
Philipp Schubert  1 , Rainer Fietkau  2 , Markus Hecht  2
Affiliations
Comment

[Relevance of radiotherapy in the context of increasingly effective systemic therapies for metastatic NSCLC-evidence from a recurrence analysis after immune checkpoint inhibitors]

[Article in German]
Philipp Schubert et al. Strahlenther Onkol. 2021 Dec.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Gomez DR, et al. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol. 2019;37(18):1558–1565. doi: 10.1200/JCO.19.00201. - DOI - PMC - PubMed
    1. Bauml JM, et al. Pembrolizumab after completion of locally ablative therapy for oligometastatic non-small cell lung cancer: a phase 2 trial. JAMA Oncol. 2019;5(9):1283–1290. doi: 10.1001/jamaoncol.2019.1449. - DOI - PMC - PubMed
    1. Friedrich M, et al. Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy. Cancer Immunol Immunother. 2019;68(10):1689–1700. doi: 10.1007/s00262-019-02373-1. - DOI - PMC - PubMed
    1. Schubert P, et al. Prospective evaluation of all-lesion versus single-lesion radiotherapy in combination with PD-1/PD-L1 immune checkpoint inhibitors. Front Oncol. 2020;10:576643. doi: 10.3389/fonc.2020.576643. - DOI - PMC - PubMed
    1. Ruckert M, et al. Immune modulatory effects of radiotherapy as basis for well-reasoned radioimmunotherapies. Strahlenther Onkol. 2018;194(6):509–519. doi: 10.1007/s00066-018-1287-1. - DOI - PubMed

MeSH terms

Substances